Key result
Perioperative beta-blockers show conflicting evidence for reducing cardiac complications in major trials.
Why the study?
Convincing evidence for beta-blocker use in the perioperative period exists, but large randomized trials show controversial results leading to differing guideline recommendations.
Conflicting perioperative beta-blocker evidence warrants individualized decisions; leaves open standardized guideline reconciliation and targeted trials.
Optimization of the pharmacotherapy in preoperative period is the cornerstone of the concept of risk modification of cardiovascular complications in the perioperative period. Therefore, special attention has recently been focused on the use of beta-blockers in the postoperative period. Nowadays convincing evidence base for the use of this class of drugs in the perioperative period that was the basis for the development of clinical guidelines is accumulated. Moreover, results of large randomized trials of beta-blockers are controversial. This has resulted in significant differences in the classes of recommendations and levels of evidence. Analysis of the results of basic researches and the provisions of recommendations of the international and national professional medical societies on the use of beta-blockers in patients with cardiovascular disease to reduce the risk of cardiac complications in the perioperative period for planned extracardiac surgical procedures is presented.
No takes yet. Share an insight, caveat, or question.
Samoylenko et al. (2013) conducted a review in Cardiovascular disease undergoing planned extracardiac surgical procedures. Beta-blockers was evaluated on Cardiac complications. A review of current evidence and guidelines reveals controversial results from large randomized trials regarding the use of beta-blockers to reduce cardiac complications in the perioperative period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: